Clinical characteristics
| All patients (n=46) | |
| Age, years | 65±9 |
| Gender, male (%) | 36 (78) |
| Body surface area, m2 | 1.96±0.18 |
| Current smoker (%) | 7 (15) |
| Hypertension (%) | 9 (20) |
| Diabetes mellitus (%) | 0 (0) |
| IHD (%) | 5 (11) |
| Stroke (%) | 1 (4) |
| Intermittent atrial fibrillation (%) | 6 (13%) |
| NYHA class 2 or 3 | 18 (39%) |
| FEV1, L/min | 3.2±0.78 |
| eGFR, mL/min | 80±12 |
| Systolic blood pressure | 134±12 |
| Haemoglobin (mmol/l) | 8.0±0.8 |
| Haematocrit | 0.38±0.03 |
| Medication | |
| ACEi/ARB | 10 (24%) |
| β blocker | 5 (11%) |
| Calcium channel blocker | 6 (13%) |
| Diuretic | 10 (24%) |
| Anticoagulation | 5 (11%) |
| Echocardiographic characteristics | |
| LVEF (%) | 70±7 |
| ERO (cm2) | 0.50±0.25 |
| Regurgitant volume (ml) | 84±46 |
| Bileaflet prolapse (%) | 14 (30%) |
| Posterior prolapse (%) | 41 (89%) |
| Anterior prolapse (%) | 17 (37%) |
| Flail leaflet (%) | 11 (24%) |
| Ruptured chord (%) | 22 (52%) |
Data are number and (%) or mean±SD.
ACEi/ARB, ACE inhibitor / angiotensin 2 receptor blocker; ERO, effective regurgitant orifice; FEV1, forced expiratory volume (1 sec); IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class; eGFR, estimated glomerular filtration rate.